The use of physiologically based pharmacokinetic (PBPK) models has increased significantly in recent years, expanding beyond the traditional role in environmental chemical risk assessment to other industries and research sectors such as pharmaceutical development, consumer product safety assessment, and clinical or medicinal practice.